Skip to content
BioMarin
-
BioMarin partners with Profluent to develop AI-designed enzyme therapies in USA
Profluent will conduct the computational design work using its Profluent Protein Atlas, a dataset containing more than 115 billion unique protein sequences.
-
BioMarin to acquire Alesta Therapeutics for US$490M to secure HPP drug candidate
The deal will give BioMarin access to ALE1, Alesta’s lead clinical-stage candidate for hypophosphatasia (HPP), a rare genetic bone disorder.
-
BioMarin completes US$4.8B acquisition of Amicus Therapeutics to expand rare disease portfolio
The acquisition brings Amicus Therapeutics fully under BioMarin’s global operations, integrating its late-stage and commercial-stage rare disease assets into BioMarin’s established infrastructure.